WB, IHC-Bond, IHC-P
H
Endogenous
45-50
Rabbit IgG
#Q08722
961
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| IHC Leica Bond | 1:100 - 1:400 |
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #97253.
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu72 of human CD47 protein.
Background
CD47 is a five-pass transmembrane protein expressed on all normal cells. It binds to the SIRPα that is expressed on myeloid cells, including macrophages, and neuronal cells in the central nervous system. Binding of CD47 to SIRPα promotes phosphorylation of tyrosine residues in the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within the SIRPα cytoplasmic tail, inhibiting macrophage phagocytosis toward CD47-expressing cells. In this way, CD47 serves as a "don't eat me" signal or a marker of "self", functioning as an innate immune checkpoint. Additionally, CD47 was reported to modulate lymphocyte cell activation and proliferation (1-3). CD47 is overexpressed in many types of cancer. The expression level of CD47 on cancer cells is negatively associated with the response to therapies, and low expression on tumor cells is associated with a better prognosis and survival. Reagents that can block CD47-SIRPα interaction are being actively pursued for therapeutic applications (4,5). In addition to SIRPα, other proteins have been reported to bind to CD47. Thrombospondin-1 (TSP1) competes with SIRPα to bind to CD47 in the extracellular region and activates signaling pathways downstream of CD47 (6). CD47 can laterally associate with VEGFR2, FAS, and certain integrins in different contexts, and influences their downstream signaling (7-9). CD47 can be shed from the cell surface by proteolytic cleavage. In addition, CD47 is present on extracellular vesicles including exosomes, suggesting additional extracellular signaling potential (10).
- Murata, Y. et al. (2014) J Biochem 155, 335-44.
- Legrand, N. et al. (2011) Proc Natl Acad Sci USA 108, 13224-9.
- Barclay, A.N. and Van den Berg, T.K. (2014) Annu Rev Immunol 32, 25-50.
- Weiskopf, K. (2017) Eur J Cancer 76, 100-109.
- Matlung, H.L. et al. (2017) Immunol Rev 276, 145-164.
- Roberts, D.D. et al. (2012) Matrix Biol 31, 162-9.
- Kaur, S. et al. (2010) J Biol Chem 285, 38923-32.
- Azcutia, V. et al. (2013) Mol Biol Cell 24, 3358-68.
- Quesada, A.J. et al. (2005) Cell Death Differ 12, 649-58.
- Soto-Pantoja, D.R. et al. (2015) Crit Rev Biochem Mol Biol 50, 212-30.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.